PHARMACIE KERAUDRAN ET ASSOCIES : revenue, balance sheet and financial ratios

PHARMACIE KERAUDRAN ET ASSOCIES is a French company founded 11 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PLUVIGNER (56330), this company of category PME shows in 2022 a revenue of 3.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE KERAUDRAN ET ASSOCIES (SIREN 802765412)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C 3 130 585 € N/C N/C N/C N/C 2 549 303 €
Net income 306 617 € 263 973 € 246 402 € 332 012 € 278 248 € 286 828 € 286 656 € 273 955 € 225 844 €
EBITDA N/C N/C N/C 458 399 € N/C N/C N/C N/C 416 828 €
Net margin N/C N/C N/C 10.6% N/C N/C N/C N/C 8.9%

Revenue and income statement

In 2025, PHARMACIE KERAUDRAN ET ASSOCIES generates positive net income of 307 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 226 k€ -> 307 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

306 617 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 6%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 83%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

5.55%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

83.128%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

6.5%

Solvency indicators evolution
PHARMACIE KERAUDRAN ET ASSOCIES

Sector positioning

Debt ratio
5.55 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent

In 2025, the debt ratio of PHARMACIE KERAUDRAN ET AS... (5.55) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
83.13% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent +9 pts over 3 years

In 2025, the financial autonomy of PHARMACIE KERAUDRAN ET AS... (83.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 211.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

211.539

Liquidity indicators evolution
PHARMACIE KERAUDRAN ET ASSOCIES

Sector positioning

Liquidity ratio
211.54 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good

In 2025, the liquidity ratio of PHARMACIE KERAUDRAN ET AS... (211.54) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE KERAUDRAN ET ASSOCIES

Positioning of PHARMACIE KERAUDRAN ET ASSOCIES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE KERAUDRAN ET ASSOCIES is estimated at 4 870 647 € (range 3 305 244€ - 7 642 716€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
3305k€ 4870k€ 7642k€
4 870 647 € Range: 3 305 244€ - 7 642 716€
NAF 5 année 2025

Valuation method used

Net Income Multiple
306 617 € × 15.9x = 4 870 647 €
Range: 3 305 244€ - 7 642 717€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE KERAUDRAN ET ASSOCIES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE KERAUDRAN ET ASSOCIES

What is the revenue of PHARMACIE KERAUDRAN ET ASSOCIES ?

The revenue of PHARMACIE KERAUDRAN ET ASSOCIES in 2022 is 3.1 M€.

Is PHARMACIE KERAUDRAN ET ASSOCIES profitable?

Yes, PHARMACIE KERAUDRAN ET ASSOCIES generated a net profit of 307 k€ in 2025.

Where is the headquarters of PHARMACIE KERAUDRAN ET ASSOCIES ?

The headquarters of PHARMACIE KERAUDRAN ET ASSOCIES is located in PLUVIGNER (56330), in the department Morbihan.

Where to find the tax return of PHARMACIE KERAUDRAN ET ASSOCIES ?

The tax return of PHARMACIE KERAUDRAN ET ASSOCIES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE KERAUDRAN ET ASSOCIES operate?

PHARMACIE KERAUDRAN ET ASSOCIES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.